Gai W, Wu S, Li B, Zhang Y, Wang Z, Teng Y, Luo G,. Pocket-Based Generative Diffusion Model Accelerates Potent Influenza A Hemagglutinin Inhibitor Discovery. J Med Chem. 2026 Feb 13
The deep generative model has recently advanced 3D chemical space exploration but overlooked the balance between target affinity and structural rationality, limiting their effectiveness in drug discovery. Herein, we established a novel dual conditional diffusion model (DCDM) that leveraged ligand-protein interaction features to refine 3D target-based molecular generation. DCDM exhibited superiority in enhancing predicted binding affinity while maintaining high structural rationality and diversity. Subsequently, we applied DCDM to optimize penindolone (PND), a marine-derived lead compound from our laboratory, targeting influenza A hemagglutinin (HA). Efficiently, a promising candidate (compound C2e) was successfully obtained from eight synthesized derivatives inspired by the DCDM-generated molecules, with a 26-fold higher affinity for HA. Notably, C2e exhibited a 10-fold decrease in IC50 compared with the parent compound PND. Further in vivo assessments demonstrated its potent antiviral activity and safety. All results indicate that DCDM is a valuable generative model, capable of accelerating drug development in real-world applications.
See Also:
Latest articles in those days:
- [preprint]The mammalian-adaptive PB2-E627K substitution preserves viral fitness of clade 2.3.4.4b H5N1 HPAIV in birds 6 hours ago
- Mallard super-shedders of avian influenza exhibit distinct cloacal microbial abundance profiles 10 hours ago
- A digitally immune-optimized influenza vaccine broadly neutralizes swine and human H1N1 influenza viruses and protects from heterologous challenge 10 hours ago
- Associations between vaccine misinformation and influenza vaccine uptake: a population-based interrupted time-series study in China 10 hours ago
- Infection and transmission dynamics of bovine and human influenza A H5N1 viruses in mouse and hamster models 11 hours ago
[Go Top] [Close Window]


